TY - JOUR
T1 - Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer
AU - Moretto, Roberto
AU - Cremolini, Chiara
AU - Rossini, Daniele
AU - Pietrantonio, Filippo
AU - Battaglin, Francesca
AU - Amennitto, Alessi
AU - Bergamo, Francesca
AU - Loupakis, Fotios
AU - Marmorino, Federica
AU - Berenato, Rosa
AU - Angelamarsico, Valentina
AU - Caporale, Marta
AU - Antoniotti, Carlotta
AU - Masi, Gianluca
AU - Salvatore, Lisa
AU - Borelli, Beatrice
AU - Fontanini, Gabriella
AU - Lonardi, Sara
AU - De Braud, Filippo
AU - Falconea, Alfredo
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Introduction. Right- and left-sided colorectal cancers (CRCs) differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, molecular selection in those studies was not extensive. Patients and Methods. Patients with RAS and BRAF wild-type metastatic CRC (mCRC) who were treated with single-agent anti-EGFRs or with cetuximab-irinotecan (if refractory to previous irinotecan) were included in the study. Differences in outcome between patients with right- and left-sided tumors were investigated. Results. Of 75 patients, 14 and 61 had right- and left-sided tumors, respectively. None of the right-sided tumors responded according to RECIST, compared with 24 left-sided tumors (overall response rate: 0% vs. 41%; p 5 .0032), and only 2 patients with right-sided tumors (15%) versus 47 patients with left-sided tumors (80%) achieved disease control (p, .0001). The median duration of progression-free survival was 2.3 and 6.6 months in patients with right-sided and left-sided tumors, respectively (hazard ratio: 3.97;95%confidence interval: 2.09–7.53; p,.0001). Conclusion. Patients with right-sided RAS and BRAF wild-type mCRC seemed to derive no benefit from single-agent anti- EGFRs.
AB - Introduction. Right- and left-sided colorectal cancers (CRCs) differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, molecular selection in those studies was not extensive. Patients and Methods. Patients with RAS and BRAF wild-type metastatic CRC (mCRC) who were treated with single-agent anti-EGFRs or with cetuximab-irinotecan (if refractory to previous irinotecan) were included in the study. Differences in outcome between patients with right- and left-sided tumors were investigated. Results. Of 75 patients, 14 and 61 had right- and left-sided tumors, respectively. None of the right-sided tumors responded according to RECIST, compared with 24 left-sided tumors (overall response rate: 0% vs. 41%; p 5 .0032), and only 2 patients with right-sided tumors (15%) versus 47 patients with left-sided tumors (80%) achieved disease control (p, .0001). The median duration of progression-free survival was 2.3 and 6.6 months in patients with right-sided and left-sided tumors, respectively (hazard ratio: 3.97;95%confidence interval: 2.09–7.53; p,.0001). Conclusion. Patients with right-sided RAS and BRAF wild-type mCRC seemed to derive no benefit from single-agent anti- EGFRs.
KW - Anti-EGFR monoclonal antibodies
KW - Left-sided tumor
KW - Metastatic colorectal cancer
KW - Right-sided tumor
UR - http://www.scopus.com/inward/record.url?scp=84981557065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981557065&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2016-0084
DO - 10.1634/theoncologist.2016-0084
M3 - Article
AN - SCOPUS:84981557065
SN - 1083-7159
VL - 21
SP - 988
EP - 994
JO - Oncologist
JF - Oncologist
IS - 8
ER -